
    
      After the screening visit, the eligible patient population randomly receive one of the three
      following topical drugs:

        -  BioChaperone™ PDGF-BB 12.5 µg/cm²/application for 20 weeks,

        -  BioChaperone™ PDGF-BB 25 µg/cm²/application for 20 weeks, or

        -  BioChaperone™ PDGF-BB 4 µg/cm²/application for 20 weeks, or

        -  Beclapermin gel 6.25 µg/cm²/application for 20 weeks.

      The assessment schedule for all the four groups is weekly once (7 day duration) till the 8th
      week (visit 10) and once in two weeks (14 day duration) thereafter till the end of study. The
      maximum number of visits expected is 16. The study data is presented at the end of 20 weeks.
    
  